The stock-market impact of millennial investors has gotten overblown amid declining trading volumes — and it's actually the older crowd that's exerted more influence, JPMorgan says

News, market analysis, investment scam prevention tips and more ✔️ Your source for latest asset management news and information. This magazine is crafted specifically for those who are interested in diving into the global asset management world. Reuters / Lucas JacksonOlder retail investors were "partly responsible" for the market's price swings through October and November, while younger traders played "a rather modest role," JPMorgan strategists said Tuesday. While the younger group typically invests in individual stocks and options, the older cohort more often uses funds to invest. Older investors have been selling equity funds and buying bond funds through most of 2020, according to the bank. This activity has acted as a drag on the stock market. Regardless of age, retail investors' trading volumes have fallen from roughly 26% of all market volume in June to just 16% in September. The decline "raises questions" about the narrative that retail investors were behind the market's summer rally, JPMorgan said. Visit the Business Insider homepage for more stories. Despite millennial investors making headlines over the summer, older investors played a bigger role in driving the market's recent swings, JPMorgan strategists said Tuesday. A surge in retail-investor trading activity coincided with stocks' climb to record highs in September, leading Wall Street to wonder whether individual traders were a new market driver. First-time millennial and Generation Z investors garnered unique attention for their risky day-trading habits and interest in highly volatile To keep reading about The stock-market impact of millennial investors has gotten overblown amid declining trading volumes — and it's actually the older crowd that's exerted more influence, JPMorgan says, Click on the link. Seoul, Korea
http://dlvr.it/RmT5c0

Comments

Popular posts from this blog

AstraZeneca Begins Phase I Trial Of AZD7442 Against COVID-19 – Quick Facts

Coronavirus Hasn't Diminished Tech Stocks' Allure

Henlius Plans to File the NDA of Novel anti-PD-1 mAb HLX10 for the Treatment of MSI-H Solid Tumours, the Phase 2 Clinical Trial has Met the Primary Endpoint